Table of Contents
- PDF Downloads
- Letter of transmittal
- User guide
- Part One: Overview
- Part Two: Our role and governance
- Part Three: Our performance
- Part Four: Our people
- Part Five: Future trends in blood management and horizon scanning
- Part Six: Our finances
- Part Seven: Appendices
- Part Eight: Index
- TABLES
- 1.1 Five years of achievements, 2003–08
- 2.1 The National Blood Agreement: objectives of governments
- 2.2 Government provided funding to procure and manage the blood supply
- 3.1 Extract of NBA key performance indicators reported in the Health and Ageing Portfolio Budget Statements 2007–08
- 3.2 Blood and blood-related products purchased in 2006–07 and 2007–08, by supplier
- 3.3 New blood product contracts negotiated, 2007–08
- 3.4 Australian Red Cross Blood Service, annual funding commitments, 2003–08
- 3.5 Value of Australian Red Cross Blood Service annual capital plan ($ million), 2005–08
- 3.6 Key performance indicators for the CSL Ltd Plasma Products Agreement
- 3.7 Imported recombinant blood product contract key performance indicators
- 3.8 Types of red cell usage studies being undertaken within the states and territories
- 3.9 Issues of blood products 2006–07 and 2007–08
- 3.10 Terms of Reference for the Review of Distribution Arrangements for Blood Products
- 3.11 NBA Performance indicators for JBC support, 2007–08
- 4.1 NBA staff numbers, as of 30 June 2008
- 4.2 Salary levels
- 6.1 Total resources for Outcome 1 ($ k), 2007–08
- 6.2 Total expenditure for payments over $10 300 on advertising, market research and direct mailing services, 2007–08
- 6.3 Total expenditure on consultancy services, 2005–06 to 2007–08
- 6.4 Consultancy services of $10 000 or more, 2007–08
- 6.5 Key results in financial performance
- 6.6 Key results of administered expenses
- FIGURES
- 2.1 Australian blood supply chain
- 2.2 Governance structure of the Australian blood sector
- 2.3 The NBA’s organisational structure
- 2.4 Executive management monthly program
- 3.1 Performance of National Blood Authority: actual funding versus budgets
- 3.2 Product mix of red blood cells issued by the Australian Red Cross Blood Service, 2003–08
- 3.3 Product mix of platelets issued by the Australian Red Cross Blood Service, 2003–08
- 3.4 Examples of emerging theme mapping
- 3.5 Red blood cells issued per 1000 head of population
- 3.6 Platelets issued per 1000 head of population
- 3.7 Issues for IVIg products
- 3.8 Issues of IVIg per 1000 head of population
- 3.9 Market share of recombinant factor VIII issues
- 3.10 Issues of factor VIII products
- 3.11 Issues of factor IX products
- 3.12 Issues of recombinant factor VIIa products
- 3.13 Issues of total factor VIII per 1000 head of population
- 3.14 Issues of total factor IX per 1000 head of population
- 3.15 Market share for diagnostic reagent supply
- 3.16 Criteria For the Clinical Use of Intravenous Immunoglobin (IVIg) in Australia: book and Quick Reference Guide
- 3.17 Top ten uses of intravenous immunoglobulin (IVIg)
- 3.18 Initial Australian Haemovigilance Report
- 5.1 The scope of the Review of New Technologies, New Techniques and New Products
- 6.1 Composition of NBA assets at 30 June 2008
- 6.2 Composition of contributions from all governments, 2007–08
PDF Downloads
The following documents have been made available in Adobe Acrobat format. They can be viewed using Adobe Reader, a free download from Adobe.
- Full Document 2.4mb)
- Letter of Transmittal (36kb)
- User Guide (71kb)
- Part One: Overview (255kb)
- Part Two: Our Role and Governance (291kb)
- Part Three: Our Performance (902kb)
- Part Four: Our People (159kb)
- Part Five:Future trends in blood management and horizon scanning (150kb)
- Part Six: Our Finances (153kb)
- Part Seven: Appendices (538kb)
- Part Eight: Index (88kb)